Phio Pharmaceuticals (PHIO) Cash from Financing Activities (2011 - 2025)

Phio Pharmaceuticals (PHIO) has 15 years of Cash from Financing Activities data on file, last reported at $12.4 million in Q4 2025.

• Quarterly Cash from Financing Activities rose 815.5% year-over-year to $12.4 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $14.5 million (up 9.82% YoY) and the FY2025 annual result came in at $23.6 million, up 491.59% from the prior year.
• Cash from Financing Activities rose to $12.4 million in Q4 2025, from $2.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $21.7 million in Q1 2021 to a low of -$38000.0 in Q1 2023.
• A 5-year average of $3.8 million and a median of $1.4 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities plunged 100.12% — and 2025, when it surged 229425.0%.
• Tracing PHIO's Cash from Financing Activities over 5 years: stood at -$1000.0 in 2021, then jumped by 300.0% to $2000.0 in 2022, then soared by 120050.0% to $2.4 million in 2023, then tumbled by 43.61% to $1.4 million in 2024, then jumped by 815.5% to $12.4 million in 2025.
• The last three Cash from Financing Activities figures came in at $12.4 million (Q4 2025), $2.0 million (Q3 2025), and $40000.0 (Q2 2025), per Business Quant data.